AbbVie (NYSE:ABBV) Given “Buy” Rating at Guggenheim

AbbVie (NYSE:ABBV)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $288.00 price objective on the stock. Guggenheim’s price objective indicates a potential upside of 4.65% from the stock’s previous close.

Several other equities analysts have also issued reports on ABBV. Morgan Stanley lifted their target price on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday. Rothschild & Co Redburn raised their price objective on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. BNP Paribas Exane lifted their price objective on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Finally, Canaccord Genuity Group raised their price target on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $276.64.

AbbVie Stock Performance

Shares of NYSE ABBV traded up $2.77 during trading hours on Friday, hitting $275.19. The company’s stock had a trading volume of 573,191 shares, compared to its average volume of 6,399,344. The business has a 50-day simple moving average of $258.56 and a 200-day simple moving average of $236.35. The stock has a market cap of $486.21 billion, a price-to-earnings ratio of 77.67, a P/E/G ratio of 1.23 and a beta of 0.24. AbbVie has a 12 month low of $190.75 and a 12 month high of $276.61.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period last year, the company posted $2.97 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts forecast that AbbVie will post 14.01 EPS for the current year.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. ACT Advisors LLC. boosted its holdings in AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after acquiring an additional 41 shares during the last quarter. Willner & Heller LLC lifted its holdings in AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after acquiring an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC raised its holdings in AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after buying an additional 43 shares during the period. Fielder Capital Group LLC boosted its holdings in AbbVie by 1.7% during the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after purchasing an additional 43 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC raised its stake in shares of AbbVie by 0.4% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock worth $2,996,000 after purchasing an additional 43 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts raised targets and reaffirmed bullish ratings. Guggenheim reaffirmed its “buy” rating with a $288 price target, while JPMorgan raised its target to $300 and maintained an “overweight” rating. Cantor Fitzgerald also lifted its target to $290 and kept an “overweight” rating. The revisions indicate continued confidence in AbbVie’s earnings outlook and growth prospects.
• Positive Sentiment: Temab-A received two FDA Breakthrough Therapy Designations. AbbVie’s telisotuzumab adizutecan (Temab-A, or ABBV-400) received the designations for potential use in colorectal cancer and non-small cell lung cancer. The FDA status may accelerate development and review, strengthening the perceived value of AbbVie’s oncology pipeline. FDA Grants Breakthrough Therapy Designations to AbbVie’s Temab-A
• Positive Sentiment: Additional oncology data supported pipeline optimism. An AbbVie and Genmab combination involving epcoritamab reportedly reduced the risk of progression or death by 51% in diffuse large B-cell lymphoma, providing another favorable signal for AbbVie’s cancer portfolio.
• Positive Sentiment: Momentum has pushed ABBV to new one-year highs. The stock recently set consecutive 52-week highs, suggesting that analyst upgrades and pipeline news are reinforcing positive investor sentiment.
• Neutral Sentiment: Valuation and expectations remain important risks. AbbVie is trading near its 12-month high with a relatively elevated price-to-earnings ratio, so further gains may depend on the company delivering against strong earnings and pipeline expectations. Recent coverage also noted mixed growth outlooks across large pharmaceutical companies, despite higher price targets.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.